Key Takeaways:
- Households that include at least one GLP-1 user have reduced their grocery spending by around 6% after six months of taking the medication, according to a study conducted by Cornell University and Numerator. The impact is even more significant for higher-income households, with spending decreasing by nearly 9%.
- The study revealed a notable decrease in the purchase of calorie-dense, processed items, with an 11% drop in savory snacks.
- With close to 15 million U.S. adults using GLP-1 medications, there is a noticeable shift in the types of foods being consumed. This shift is prompting changes in what CPG companies offer and how they market their products.
Insightful Analysis:
As the number of consumers taking GLP-1 drugs like Ozempic and Wegovy increases, there is a noticeable impact on food preferences, leading to a decline in sales for certain food and beverage categories.
The study by Cornell and Numerator highlighted that a 6% reduction in grocery spending post GLP-1 adoption translates to an annual decrease of $416 per household. For households earning over $125,000, the yearly grocery spending decreased by $690.
Snacking categories are experiencing the most significant decline, with purchases of items such as chips, baked goods, sides, and cookies seeing reductions ranging from 6.7% to 11.1%.
Notably, Hershey’s CEO mentioned a “mild” impact from GLP-1 medications on their sales.
While there was a slight increase in spending on items like fresh produce and yogurt among weight-loss users, the overall composition of grocery baskets became healthier as people reduced unhealthy purchases more than adding healthier options.
Researchers emphasized the potential for GLP-1 medications to reshape consumer food preferences significantly, a trend that holds crucial implications for the food industry as adoption rates rise.
With increasing data on the impact of weight-loss drugs on food consumption, it comes as no surprise that CPG companies are adapting to either benefit from or mitigate the effects.
Nestlé recently introduced a pre-meal drink under its Boost brand to help curb hunger and enhance satiety, targeting consumers on weight-loss medications. Additionally, they launched Vital Pursuit, a brand tailored to individuals focused on weight management and taking GLP-1 medications.
Conagra Brands, known for Slim Jim, is launching a lineup of Healthy Choice products labeled as “GLP-1 friendly,” becoming the first major food brand to cater to users of popular weight-loss medications.
Morgan Stanley analysts predict that the global market for obesity drugs will hit $105 billion by 2030. While uncertainties remain around the long-term effects of GLP-1 drugs, companies like Nestlé and Conagra demonstrate a proactive approach in addressing the potential impact through product innovation and marketing strategies.